Virios Therapeutics

About:

Virios Therapeutics is a clinical-stage biopharmaceutical company developing novel antiviral therapies for fibromyalgia and other diseases.

Website: https://www.virios.com/

Top Investors: William Buchalter

Description:

Virios Therapeutics is a clinical-stage biopharmaceutical company developing novel antiviral therapies for fibromyalgia and other diseases. The company is driven to improve patient outcomes by finally answering an underlying cause of fibromyalgia and related conditions. The overactive immune response related to activation of tissue-resident Herpes Simplex Virus-1 (HSV-1) has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel disease (IBS), chronic fatigue syndrome (CFS), and functional somatic syndrome, all of which are characterized by a waxing and waning manifestation of the disease. Virios Therapeutics' IMC-1, is a combination of antiviral therapy designed to synergistically suppress Herpes Simplex Virus-1activation and replication, with the end goal of reducing viral-mediated disease burden. In a Phase 2a proof-of-concept trial for fibromyalgia, IMC-1 provided statistically significant improvement versus placebo in the primary endpoint of pain reduction. The company plans to enter a Phase 2b trial in the 1Q21, with topline data expected in the 1Q22. Virios Therapeutics was founded in 2012 and is headquartered in Alpharetta, Georgia.